Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

2.

Factor V Leiden: should we screen oral contraceptive users and pregnant women?

Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR.

BMJ. 1996 Nov 2;313(7065):1127-30. Review.

3.

Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis.

Sarasin FP, Bounameaux H.

Thromb Haemost. 1994 Mar;71(3):286-91.

PMID:
8029791
4.

Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis.

Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP; Investigators of the "Durée Optimale du Traitement AntiVitamines K" (DOTAVK) Study.

Circulation. 2001 May 22;103(20):2453-60.

5.

Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.

Marchetti M, Pistorio A, Barosi G.

Thromb Haemost. 2000 Nov;84(5):752-7. Erratum in: Thromb Haemost 2000 Dec;84(6):1112.

PMID:
11127850
6.

Duration of anticoagulant treatment for venous thrombosis.

Raskob GE.

Curr Opin Pulm Med. 1997 Jul;3(4):286-90. Review.

PMID:
9262115
7.

The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.

Eichinger S, Pabinger I, Stümpflen A, Hirschl M, Bialonczyk C, Schneider B, Mannhalter C, Minar E, Lechner K, Kyrle PA.

Thromb Haemost. 1997 Apr;77(4):624-8.

PMID:
9134632
8.

Antithrombotic strategy after total hip replacement. A cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis.

Sarasin FP, Bounameaux H.

Arch Intern Med. 1996 Aug 12-26;156(15):1661-8. Erratum in: Arch Intern Med 1996 Nov 25;156(21):2487.

PMID:
8694664
9.

Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.

Price DT, Ridker PM.

Ann Intern Med. 1997 Nov 15;127(10):895-903. Review.

PMID:
9382368
10.

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E.

N Engl J Med. 1997 Feb 6;336(6):393-8.

11.

Extended oral anticoagulant therapy after a first episode of pulmonary embolism.

Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P; Warfarin Optimal Duration Italian Trial Investigators.

Ann Intern Med. 2003 Jul 1;139(1):19-25.

PMID:
12834314
12.

Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model.

Vink R, Kraaijenhagen RA, Levi M, Büller HR.

J Thromb Haemost. 2003 Dec;1(12):2523-30.

13.

Recurrent venous thrombosis with factor V Leiden mutation.

Meenakshi-Sundaram S, Sridhar R, Jithendrian JJ, Durai RN, Arunkumar MJ, Sundar B.

J Assoc Physicians India. 2005 Jul;53:642-4.

PMID:
16190136
14.

Oral anticoagulant therapy in venous thromboembolism.

Cosmi B, Palareti G.

Semin Vasc Med. 2003 Aug;3(3):303-14. Review.

PMID:
15199464
15.

The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden).

Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A.

N Engl J Med. 1997 Feb 6;336(6):399-403.

17.

Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation.

Manten B, Westendorp RG, Koster T, Reitsma PH, Rosendaal FR.

Thromb Haemost. 1996 Oct;76(4):510-3.

PMID:
8902987
18.

The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism.

Eichinger S, Weltermann A, Mannhalter C, Minar E, Bialonczyk C, Hirschl M, Schönauer V, Lechner K, Kyrle PA.

Arch Intern Med. 2002 Nov 11;162(20):2357-60.

PMID:
12418950
19.

Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.

Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W; Warfarin Optimal Duration Italian Trial Investigators.

N Engl J Med. 2001 Jul 19;345(3):165-9.

20.

Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs.

Bounameaux H, de Moerloose P, Sarasin FP.

Blood Coagul Fibrinolysis. 1996 Jul;7(5):507-14. Review.

PMID:
8874860

Supplemental Content

Support Center